Amicus Therapeutics Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Great West Life Assurance Co. Can raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exch

Blueshift Asset Management LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 86.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange

Axa boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The

Amalgamated Bank lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Secur

Dynamic Technology Lab Private Ltd lessened its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 26.0% during the 4th quarter, according to the company in its most recent Form 13F filing with th

The COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $9.00, f

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, BidAskClub reports

Q4 2019 Amicus Therapeutics Inc Earnings Call

AlphaCrest Capital Management LLC lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 27.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC

Amicus says global supply chains for Galafold have not been interrupted FOLD

Amicus Therapeutics (FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company has